A key drug used in the 2022 global outbreak of mpox has been found to be ineffective against the new strain currently spreading across Africa. Via Politico:
The antiviral, tecovirimat, did not reduce the duration of lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), according to the initial results of a placebo-controlled trial run by researchers in the DRC and the U.S.
Clade I is a more dangerous type of mpox — formerly known as monkeypox — than clade II which caused a global outbreak in 2022, and is associated with more severe illness and higher fatality rates.
Clade I is disproportionately affecting children, a trend not seen in the 2022 outbreak, and triggered the World Health Organization to declare a global emergency on Wednesday.
Read the full report here. Reminder – while mpox isn’t a “gay disease,” it can be transmitted through skin-on-skin contact. Keep that in mind, and if you haven’t gotten the Jynneos vaccine, you might want to consider that.
U.S. NIH finds that Tecovirimat, the Mpox drug many countries were stockpiling, is not effective against the new clade I strain! Read more below:https://t.co/xmpFYv7ebZ pic.twitter.com/mUsVCJRICp
— Patientmakt (@PatientCV) August 16, 2024
Discover more from The Randy Report
Subscribe to get the latest posts sent to your email.